# Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer

> **NCT02948543** · PHASE3 · UNKNOWN · sponsor: **University of Sydney** · enrollment: 501 (actual)

## Conditions studied

- Bladder Cancer

## Interventions

- **BIOLOGICAL:** Bacillus of Calmette-Guerin (BCG)
- **DRUG:** Mitomycin (MM)

## Key facts

- **NCT ID:** NCT02948543
- **Lead sponsor:** University of Sydney
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2013-07
- **Primary completion:** 2024-12
- **Final completion:** 2024-12
- **Target enrollment:** 501 (ACTUAL)
- **Last updated:** 2023-06-18

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02948543

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02948543, "Adding Mitomycin to BCG as Adjuvant Intravesical Therapy for High-risk Non-Muscle-invasive Bladder Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT02948543. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*